HIF1α identified as key regulator that induces cancer-killing ability of hypoxic T cells, playing a role in ICB resistance.
Stockhead on MSN9d
Dr Boreham’s Crucible: Can this cancer drug hopeful meet a desperate unmet need?In its pursuit of a cancer drug for pancreatic cancer and possibly ovarian cancer, Amplia has history on its side.
Researchers developed a computational model to optimize drug selection for chronic myelogenous leukemia (CML), tailoring ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Zacks.com on MSN8h
Tempus AI Stock Falls Despite Collaboration Announcement With GenialisTempus AI, Inc. TEM recently announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company.
it showed no inhibition of the anti-tumour effect of DDP. This may be because LIN itself has anti-tumour abilities and does not promote tumor growth. However, a synergistic inhibitory effect between ...
Effect of ethanolic extract of Morinda citrifolia L on B16-F10 cell growth inhibition B16-F10 cells at 80% confluence ... It has shown to inhibit the growth of tumor cells in experimental model ...
A study has found targeting a protein called endocan and its related signaling pathway could be a promising new approach for treating glioblastoma, an aggressive and lethal type of brain cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback